Takeuchi T, et al. - The safety as well as efficacy of sirukumab, as monotherapy in Japanese patients having rheumatoid arthritis (RA) refractory to methotrexate or sulfasalazine was assessed herein. Results suggested comparable safety between the two treatment groups ie, patients who received sirukumab 50 mg once every 4 weeks (q4w) or 100 mg once every 2 weeks (q2w) subcutaneously through 52 weeks. Furthermore, it was noted that the 52-week administration of sirukumab at 50 mg q4w and 100 mg q2w was generally tolerable and with measurable efficacy in Japanese patients with RA refractory to methotrexate and sulfasalazine.